There were several data errors in the article “Dose Escalation Study of No-Carrier-Added 131I-Metaiodobenzylguanidine for Relapsed or Refractory Neuroblastoma: New Approaches to Neuroblastoma Therapy Consortium Trial,” by Matthay et al. (J Nucl Med. 2012;53:1155–1163). In Tables 4 and 6, the activity received by patient N086 was 692 [not 688] MBq/kg. In Table 6, this patient (whose data appear in the last row) had an MIBG response of PR [not CR] and a CT response of CR [not PR]. In addition, on page 1160 the “Response” results should have stated that 2 [not 1] of 11 patients with a measurable soft-tissue lesion had a soft-tissue response, and the “Dose Escalation and Toxicity” results should have stated that 2 [not 3] other patients assigned to level 4 received an adjusted dose of 666 MBq/kg. Finally, the text immediately after this statement should have read as follows: “The sixth and last patient who would have been assigned to level 4 was assigned to level 3 (666 MBq/kg), providing 6 patients evaluable at dose level 3 for response and to document safety, since level 4 was by then deemed infeasible” [not “providing 6 patients evaluable at dose level 3 to document safety”]. The authors regret the errors.
- © 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.